Mycoplasma genitalium in the US (MyGeniUS): Surveillance Data from Sexual Health Clinics in Four US Regions

Mycoplasma genitalium (MG) is on the CDC Watch List of Antimicrobial Resistance Threats yet there is no systematic surveillance to monitor change. We initiated surveillance in sexual health clinics in six cities, selecting a quota sample of urogenital specimens tested for gonorrhea and/or chlamydia. We abstracted patient data from medical records and detected MG and macrolide resistance mutations (MRM) by nucleic acid amplification testing. We employed Poisson regression to estimate adjusted prevalence ratios (aPR) and 95% confidence intervals (CI), adjusting for sampling criteria (site, birth-sex, symptom status). From October-December 2020 we tested 1,743 urogenital specimens: 57.0% from males, 46.1% from non-Hispanic Black people, 43.8% from symptomatic patients. MG prevalence was 16.6% (95%CI = 14.9-18.5) (site-specific range = 9.9%-23.5%) and higher in St Louis (aPR = 1.9; 1.27-2.85), Greensboro (aPR = 1.8; 1.18-2.79), and Denver (aPR = 1.7; 1.12-2.44) than Seattle. Prevalence was highest in people